Desvenlafaxine Succinate ER — A Non-Hormonal SNRI Option
An SNRI-based non-hormonal option used in selected menopausal patients for vasomotor symptom support, including situations where paroxetine is not preferred.
Desvenlafaxine Succinate ER
An extended-release SNRI option used in selected menopausal patients for vasomotor symptom support and considered when a non-hormonal strategy is needed.
Tamoxifen Alternative
Desvenlafaxine may be considered when a non-hormonal option is needed and paroxetine is undesirable because of tamoxifen interaction concerns.
| Protocol | Frequency | Notes |
|---|---|---|
| 50 mg | Daily | Lower individualized option, including down-titration or weaning plans |
| 100 mg | Daily | Standard higher-dose protocol when clinically needed |
- Useful when a non-hormonal vasomotor symptom approach is needed.
- Can be considered as an alternative when paroxetine is not preferred in a patient taking tamoxifen.
- Swallow ER tablets whole and review blood pressure, serotonergic medications, and withdrawal planning before changes.
- Monitor for mood changes, suicidality, hypertension, and serotonergic adverse effects.
Desvenlafaxine is an SNRI that modulates serotonin and norepinephrine pathways involved in central thermoregulation, which can help reduce hot flash burden in selected patients.
- Concomitant MAOI use or required MAOI washout windows
- Known hypersensitivity to desvenlafaxine or venlafaxine
- Caution with uncontrolled hypertension, bleeding risk, glaucoma risk, or serotonergic combinations
Common adverse effects: Nausea, dry mouth, dizziness, sweating, constipation, insomnia, and blood pressure increases may occur.
- Store at controlled room temperature.
- Swallow extended-release tablets whole; do not crush, split, or chew unless directed otherwise by the prescriber and formulation design.
- The medicine should be fine for 5 days from the shipping date at temperatures up to 105 degrees Fahrenheit.
Why might this be chosen over paroxetine?
It may be preferred in some patients needing a non-hormonal option when tamoxifen interaction concerns make paroxetine less attractive.
Can I stop it suddenly?
Rapid discontinuation can be poorly tolerated. Dose changes should be guided by the prescriber.
Partner with Genesis Compounding
A 503A-licensed compounding partner built for telehealth and physician practice workflows. Download your onboarding documents below to get started.
Fax completed forms to 385-855-1221 or email pharmacy@genesiscompounding.com